# Case Report: Lurasidone-Induced Type 2 Brugada Pattern in a Pediatric Patient

**Authors:** Ethan Start, Aldrin Enabore

PMC · DOI: 10.5811/cpcem.1573 · Clinical Practice and Cases in Emergency Medicine · 2025-05-28

## TL;DR

A 14-year-old boy developed a Brugada pattern on ECG after increasing lurasidone, but tests later ruled out Brugada syndrome, and the pattern resolved after reducing the medication.

## Contribution

This case report highlights lurasidone's potential to induce a Brugada pattern and underscores the importance of ECG monitoring in patients on antipsychotics.

## Key findings

- A type 2 Brugada pattern was observed after increasing lurasidone dosage.
- Pharmacological testing later ruled out Brugada syndrome.
- The Brugada pattern resolved after reverting to the initial lurasidone dose.

## Abstract

Brugada syndrome, a cardiac channelopathy, manifests with ventricular arrhythmia. Diagnosis relies on a type 1 Brugada electrocardiogram (ECG) pattern, while type 2 and type 3 patterns may necessitate electrophysiologic testing to uncover an underlying type 1 Brugada pattern. Differentiation between these patterns is important, as type 1 patterns pose a significantly greater risk of arrhythmia relative to types 2 and 3 counterparts.

A 14-year-old male with autism presented after a syncopal episode following a lurasidone dosage increase. His ECG revealed a type 2 Brugada pattern. He was monitored overnight in the pediatric intensive care unit, where he remained asymptomatic. After being discharged with a Holter monitor, a quaternary hospital’s procainamide challenge test weeks later contradicted an official diagnosis of Brugada syndrome, as dictated by elucidation of a type 1 Brugada pattern. After reverting to the initial lurasidone dose, a follow-up ECG after two months showed no Brugada pattern.

In syncope cases, an ECG is crucial for identifying arrhythmogenic causes, including Brugada syndrome. This case highlights an ECG suggestive of Brugada syndrome with negative pharmacological tests and resolution post-discontinuation of the offending agent. Emergency physicians should be vigilant for Brugada and long QT syndromes in patients on antipsychotic medications.

## Linked entities

- **Chemicals:** lurasidone (PubChem CID 213046), procainamide (PubChem CID 4913)
- **Diseases:** Brugada syndrome (MONDO:0015263), autism (MONDO:0005260), long QT syndrome (MONDO:0002442)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12342673/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12342673/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12342673/full.md

---
Source: https://tomesphere.com/paper/PMC12342673